Background -Nasal hyperkeratosis may cause discomfort in dogs by predisposing them to fissures and secondary bacterial infection. Approaches to treatment have been described anecdotally; the effectiveness of such therapies remains unproven.
Introduction
Canine nasal hyperkeratosis reflects an excessive multiplication of keratinocytes, their retention or a lack of desquamation. The planum nasale, which is normally smooth, pliable and shiny, becomes dry, firm and hyperplastic. 1 Nasal hyperkeratosis can be secondary to a large variety of diseases, including distemper, leishmaniasis, pemphigus foliaceus, systemic lupus erythematosus, zinc-responsive dermatosis, cutaneous lymphoma or necrolytic migratory erythema. 2 In otherwise healthy animals, this clinical presentation may be observed as a congenital hereditary disorder (as in Labrador retrievers), 3 as a senile change, or because of nasal anatomical abnormalities. 3 Nasal hyperkeratosis can be associated with footpad hyperkeratosis in some cases, usually with a similar aetiology. 2 When nasal hyperkeratosis is not associated with a systemic disease or other skin signs, it is often solely a cosmetic issue and does not necessarily justify treatment. However, it can lead to fissuring, bleeding and secondary bacterial or fungal infections which may be associated with pain. When there is no primary cause that can be addressed, treatment aims to soften and remove the excessive keratinized material. In idiopathic cases, life-long treatment is usually required. Treatments reported for idiopathic hyperkeratosis include mechanical removal of excessive keratin and topical application of agents such as petroleum jelly, propylene glycol, salicylic acid, ichthammol ointment or tretinoin gel. 2, 4 These interventions have produced variable outcomes, 5 and can be on the nose of client-owned healthy dogs with idiopathic nasal hyperkeratosis. Our objectives were (i) to determine whether a daily application of the balm for a 60 day period would improve nasal lesions (primary outcome) and (ii) to evaluate owner satisfaction and record any adverse events (secondary outcomes).
Materials and methods

Study design
The study was conducted as a randomized, double-blind, placebocontrolled clinical trial with parallel group design and two month follow-up period. Privately owned dogs were used, and both owner consent and approval from the University Ethical Committee were obtained prior to enrolling subjects.
Enrolment criteria
Client-owned dogs, irrespective of breed, sex or age, with an increased thickness of the nasal planum were enrolled. Dogs were excluded if they have received any treatment that could have modified the appearance of the planum nasale during the six weeks prior to inclusion. Dogs presenting with ulceration, depigmentation, atrophy or purulent crusts on the nose or a systemic disease that could affect the nose also were excluded from the study.
Study protocol
All dogs were evaluated by the same investigator (MC) at days (D) 0, D30 and D60. At the beginning of each visit, each dog went through a general and dermatological examination aimed at detecting any abnormalities that could fulfil the exclusion criteria. A lesion scale assessing the following four parameters was developed by the investigators for the purpose of conducting this study and has not yet been validated independently (Table 1) . Scoring was always performed at least 12 hours after the most recent application of the product. Lichenification was scored from 0 (normal nose) to 4 (exophytic projections of keratin); dryness was scored 0 if the nose was moist, or 1 if the nose was dry; suppleness was scored from 0 (spongy tissue and supple surface) to 2 (solid tissue and firm surface); and the extent of lesions was scored from 0 (no lesions) to 4 (the whole nose was affected). These four criteria scores were summed to establish the total clinical score. Thus, the higher the total score (maximum =11), the more pronounced were the lesions.
At each follow-up visit (D30 and D60) owners were asked to evaluate the product and its efficacy using scales developed by the investigators for this particular study: (i) a Visual Analog Scale (VAS) extending from severe worsening of the clinical signs to marked improvement; (ii) a numerical scale which evaluated both the owner's satisfaction and the estimated efficacy of the product on a scale of 0 to 10; and (iii) a verbal scale which evaluated the owner's overall satisfaction (not at all, slightly, moderately or very satisfied).
Tolerance
Tolerance was assessed by monitoring and recording adverse events (AEs) and withdrawals at any time during the study. Owners were asked to report any AE, even if its occurrence was not necessarily caused by or related to the product.
Study products
Dogs were randomly allocated to the Dermoscent BIO BALM â (DBB) or the placebo balm (PB) groups using an online tool (http://biostat.med.univ-tours.fr/mediawiki/images/biostat/ListeRand om.php). Dog owners and the primary investigator were blinded to group assignments. Owners in the PB group received a 50 g jar, identical in appearance to DBB but containing aqueous gelling agent with preservatives. Owners were asked to apply a small quantity of the product (approximately one Finger Tip Unit) and massage onto the nose once daily in the evening or just prior to walking or feeding, if possible. Owners were asked not to make any comments about the colour, odour or consistency of the product during the visits.
Concomitant treatments
During the study period, any other topical treatment for the nose or systemic treatment that could affect the appearance of the nose (e.g. corticosteroids, retinoids, essential fatty acid supplementation) was prohibited.
Statistical procedures
Data were analysed using the software Graphpad Prism (Graphpad Software, Inc.; La Jolla, CA, USA). An intention-to-treat analysis was performed. The normality of data was assessed by the D'Agostino & Pearson omnibus and Shapiro-Wilk tests. When data were not normally distributed, the Wilcoxon-Mann-Whitney U-test was used to compare the medians of two independent samples for each criterion at D0 and D60 and the total score. Differences with a P-value <0.05 were considered to be statistically significant. Owner evaluations were not subjected to statistical analysis. Severe (keratinized exophytic projections) *Dermatoglyphics refers to the formation of naturally occurring ridges on certain body parts.
Results
Study population
A total of 48 dogs were enrolled. Nine cases did not complete the study. One dog was withdrawn before D60 because adverse reactions occurred (sneezing, nasal pruritus) and the other eight were withdrawn for owners' personal reasons. One case was not taken in consideration for analysis because of the inability to contact the owners after D10. From the 47 dogs that were included in the analyses, 24 were males and 23 were females. French bulldogs and English bulldogs were most commonly represented (n = 26; 55% and n = 7; 15%, respectively), followed by pugs and Boxers (n = 3; 6%), and Boston terriers (n = 2; 4%). All other breeds were represented by a single dog. Mean age at enrolment was 4.4 years (range 6 months to 11 years) with 51.1% of dogs under the age of three and 30.4% over the age of eight. Twenty six dogs were allocated to the treatment (DBB) group and 21 to the PB group. The distribution of dog characteristics between groups (age, sex, breed and clinical baseline) showed no statistically significant differences, suggesting adequate randomization procedures.
Lesions
Data were not normally distributed. The Wilcoxon-MannWhitney U-test confirmed a statistical difference between the treatment groups. The total score was reduced by 36.8% after 60 days in the DBB group and by 14% in the PB group (P = 0.0016). Statistically significant improvements (P < 0.05) for each of the individual parameters were also observed (Table 2, Figure 1 ). Suppleness and lichenification were the individual criteria that improved the most within the 60 days, reaching 72.8% and 31.2%, respectively. In the PB group, the extent of lesions increased slightly (+2.3%) during the 60 day period and the suppleness score in the PB group declined by À42.1%.
Owner's satisfaction survey The opinions of 31 owners were collected. Responses are reported as descriptive data. Using the VAS, a moderate to marked improvement of the nasal lesions was observed by the owners in 81% of the DBB group against 44.4% of the PB group. In the latter, 27.8% of the owners did not notice any change in the nasal appearance and 16.7% even noticed a worsening of the lesions. Using the numerical scale, owners rated the effectiveness of DBB as 7.25 of 10 versus 5.28 of 10 for PB. Seven owners (29%) did not appreciate the use of the product because of its odour, the reluctance of the dog to receive the application, or the greasy and liquid consistency of the balm at warm temperatures. Using the verbal scale, 42.9% of owners in the DBB group were very satisfied with the response to treatment versus only 20% in the PB group; 26.7% of owners in the PB group were "not at all satisfied" versus only 9.5% in the DBB group (detailed results are presented in Figure 2 ). Some owners in the DBB (two of three) noticed a clear and rapid improvement of the lesions until D30 with no additional change thereafter, and one owner reported a more progressive and gradual progression until D60.
Assessment of safety
Three of 26 cases (11.5%) in the DBB group reported the occurrence of an AE. Erythema of the skin surrounding the nose was observed. This sign resolved spontaneously a few hours after removal of the remaining product. The three cases were associated with difficulty in application of the balm (the product was being applied not only on the planum nasale but also on the bridge of the haired skin just caudal to the nasal planum). Two of these cases were exposed to hot temperatures and direct sunlight. No AEs were reported in the placebo group.
Discussion
There are no controlled trials reporting on the treatment of localized hyperkeratosis in dogs. The present study provides evidence for the usefulness of DBB in controlling uncomplicated nasal hyperkeratosis, with each of the efficacy variables assessed being significantly better for the DBB-treated dogs than for the placebo-treated dogs. Lichenification and suppleness were the individual criteria showing most improvement in the treated group (31.2% and 72.8%, respectively), with a total score reduction of 36.8% after 60 days of a daily application. One of the limitations of the study is the use of a nonvalidated outcome scale with unknown intra-and interobserver reliability. However, all the dogs were evaluated blind, at each visit, by the same investigator which should have reduced observational biases.
It can be hypothesized that the positive outcomes observed in this study resulted from the combination of the various active ingredients contained in DBB. The essential oil of M. cajuputi contains different molecules including 1.8-cineole, with strong mucolytic, expectorant and anti-inflammatory properties, 6, 7 and other monoterpenes and sesquiterpenes with antimicrobial and analgesic properties. [8] [9] [10] Soybean oil is the main excipient of the product and contains vitamins (A, D, E and K) and essential fatty acids (linoleic, linolenic and oleic acids). 11, 12 Allantoin acts as a moisturizer of the epidermis, 13 favours desquamation by destruction of intercellular cohesive elements, 14 and stimulates skin cicatrization. [15] [16] [17] Cetyl palmitate, another excipient which is often used in cosmetic products, creates an impermeable film that prevents transepidermal water loss and therefore contributes to hydration and prolonged residence time of active ingredients. 18 Clinical improvement was also observed in the placebo group and may have been due to the moisturizing properties of the excipients. Apart from the different molecules contained in the balm, the gentle massage performed when applying the product may have also contributed to improvement via mechanical removal of the excess keratin. Although each owner had received similar instructions and demonstrations at the beginning of the study, some may have been more assiduous in applying the balm and massaging the affected area.
In hereditary nasal parakeratosis of Labrador retrievers, clinical improvement has been reported with application of propylene glycol, topical vitamin E or petroleum jelly, used separately. 2, 5 This highlights the importance of topical management and the direct action of emollient and moisturizing agents in addition to mechanical removal of crusts. Combining active ingredients with emollients, as in the tested product, may enhance efficacy. A clear improvement in clinical signs was observed after the first 30 days of treatment. This progression was less obvious during the second month. Other clinical studies should be performed to determine the ideal frequency of application for maintenance. However, this factor may be dog-dependent as we observed marked differences in the degree and rapidity of improvement between individuals (Figure S1) . Therefore, each case should be managed based on the clinician's observations. Minor AEs were observed in three of 26 dogs (11.5%) treated with DBB; manifest as alopecia and erythema of the skin around the nose which could represent contact or irritant dermatitis. Some components of the balm -such as the limonene present in cajeput essential oil -can be oxidized at high temperatures, 19 and may cause photosensitization. The clinician should inform the owner of this possible AE and advise the application of the product on the nose only, avoiding the surrounding haired skin. The product should be applied in the evening when possible to avoid direct sunlight and higher temperatures. The balm should be stored at cool temperatures (15-25°C) and should not be exposed to sunlight. 19 In conclusion, we have demonstrated that a balm containing cajeput and soybean oil, allantoin and cetyl palmitate (Dermoscent BIO BALM â ) is efficacious and well tolerated in the treatment of uncomplicated nasal hyperkeratosis of healthy dogs. When possible, manual removal of excess keratin should be associated with the topical application of the product to increase the effectiveness of the treatment. 
